Clinical Trial Update: Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ipilimumab and nivolumab in recurrent stage IV HER2-negative inflammatory breast cancer; study terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Inflammatory Breast Cancer

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Northwestern University | Conditions: HER2/Neu Negative, Recurrent Inflammatory Breast Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2019-05-28